Figure 1

Syndecan-1 is reduced at 36 weeks’ gestation and in women with underlying vascular disease. In samples collected at 36 weeks’ gestation in Sydney Australia (Cohort 1, n = 1085 controls and n = 121 SGA), circulating syndecan-1 was significant reduced (A) with an area under the receiver operator curve (AUC) of 0.67 (B). Linear regression analyses of logSyndecan-1 in women who attended the Manchester Antenatal Vascular Service (MAViS clinic; Cohort 2) and had plasma sampling across 24–34 weeks’ gestation. (C) Controls (n = 171) and women who delivered small-for gestational age (SGA) infants (with or without preeclampsia, n = 82). (D) Controls (n = 171) and women who delivered with preeclampsia (PE) and had an SGA infant (SGA/PE n = 25). (E) Controls (n = 171) and women who delivered an SGA infant (without preeclampsia, n = 57). (F) Controls (n = 171) and women who delivered with preeclampsia and an appropriately grown infant (n = 32). Individual symbols represent a single patient sample. For (A), data expressed as median ± IQR, ****p = 0.0001. In panels (C–F), the solid line is the line of best fit, while the dotted line is the 95% confidence intervals.